Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEA E-Prescribing Proposal Cites Electronic Physician Signatures Among Issues For Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug Enforcement Administration issues rules to allow electronic prescribing of Schedule II-IV controlled substances.

You may also be interested in...



Generic Substitution Of Controlled Drugs Allowed In DEA e-Prescribing Rule

The Drug Enforcement Administration says generic substitution of controlled substances will be allowed at the pharmacy level when the prescription is submitted electronically

Generic Substitution Of Controlled Drugs Allowed In DEA e-Prescribing Rule

The Drug Enforcement Administration says generic substitution of controlled substances will be allowed at the pharmacy level when the prescription is submitted electronically

BCBS Of North Carolina Offers E-Prescribing Incentive To Providers

While Medicare will start providing financial incentives to physicians to use e-prescribing starting in 2009, some private plans are already paying physicians and pharmacies to adopt the technology

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel